Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK DDI Study of Linaprazan Glurate with Clarithromycin and Midazolam
NCT05633147Phase 1Completed
- Sponsor
- Cinclus Pharma
- Start
- Nov 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of linaprazan glurate in gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (2 arms), sponsored by Cinclus Pharma. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Infinity at Day 14, Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at Day 14 and 1 more. Started Nov 2022; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
gastroesophageal reflux disease (GERD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05633147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05633147.